Wyeth, Partner, Seek OK for Schizophrenia Drug

(October 13, 2006) -- Wyeth Pharmaceuticals and Solvay Pharmaceuticals submitted a new drug application with the Food and Drug Administration Thursday seeking approval for Bifeprunox, their experimental schizophrenia treatment.

The submission is based on safety and efficacy studies that evaluated Bifeprunox for the treatment of schizophrenia in about 2,550 patients.

Schizophrenia is a chronic form of psychosis that affects about 3 million people in North America. It is characterized by hallucinations, delusions, disorganized thought and emotional blunting.

In March 2004, Solvay Pharmaceuticals of Marietta, Ga., and Wyeth entered into a collaboration agreement exclusively dedicated to neuroscience-related research and development. The companies are jointly developing and attempting to commercialize Bifeprunox and two other compounds in earlier stages of development for schizophrenia, bipolar disorder, major depressive disorder with psychotic features and other indications.

Source: Philadelphia Business Journal

Last updated: 10/06

top ~ next ~ news table of contents ~ send page to a friend

We subscribe to the HONcode principles. Verify here.